Genetic markers for diagnosis and pathogenesis of Alzheimer's disease.

[1]  Nan Hu,et al.  CD33 in Alzheimer's Disease , 2013, Molecular Neurobiology.

[2]  M. Wolfe,et al.  Alternative polyadenylation and miR‐34 family members regulate tau expression , 2013, Journal of neurochemistry.

[3]  L. Tan,et al.  Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease. , 2013, Trends in molecular medicine.

[4]  Yuan Tian,et al.  Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer's APP-CTF for terminal degradation via autophagy , 2013, Proceedings of the National Academy of Sciences.

[5]  Wei Wang,et al.  Association of GWAS-linked loci with late-onset Alzheimer's disease in a northern Han Chinese population , 2013, Alzheimer's & Dementia.

[6]  S. Hébert,et al.  Circulating microRNAs in Alzheimer’s disease: the search for novel biomarkers , 2013, Front. Mol. Neurosci..

[7]  Thomas J. Montine,et al.  MicroRNA in Alzheimer’s disease: an exploratory study in brain, cerebrospinal fluid and plasma , 2013, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[8]  S. Chung,et al.  Association of GWAS Top Hits With Late-onset Alzheimer Disease in Korean Population , 2013, Alzheimer disease and associated disorders.

[9]  H. Ye,et al.  MicroRNA-98 induces an Alzheimer’s disease-like disturbance by targeting insulin-like growth factor 1 , 2013, Neuroscience Bulletin.

[10]  Bradley T. Hyman,et al.  Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta , 2013, Neuron.

[11]  S. Lovestone,et al.  The Importance of Tau Phosphorylation for Neurodegenerative Diseases , 2013, Front. Neurol..

[12]  C. Duyckaerts,et al.  Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer’s brains , 2013, Acta Neuropathologica.

[13]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[14]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[15]  S. Cappa,et al.  Expression of the transcription factor Sp1 and its regulatory hsa-miR-29b in peripheral blood mononuclear cells from patients with Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[16]  A. Słowik,et al.  Lack of association of CR1, PICALM and CLU gene polymorphisms with Alzheimer disease in a Polish population. , 2013, Neurologia i Neurochirurgia Polska.

[17]  M. Gobbi,et al.  Good gene, bad gene: New APP variant may be both , 2012, Progress in Neurobiology.

[18]  M. López-López,et al.  Genetics of Alzheimer's disease. , 2012, Archives of medical research.

[19]  C. Zhang.  Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease. , 2012, Discovery medicine.

[20]  M. Mullan,et al.  Plasma microRNA biomarkers for detection of mild cognitive impairment , 2012, Aging.

[21]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[22]  Jason J. Corneveaux,et al.  A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline. , 2012, Human molecular genetics.

[23]  Marc Cruts,et al.  Locus-Specific Mutation Databases for Neurodegenerative Brain Diseases , 2012, Human mutation.

[24]  R. Tanzi,et al.  Role of common and rare APP DNA sequence variants in Alzheimer disease , 2012, Neurology.

[25]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[26]  Xiaozhong Peng,et al.  MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice , 2012, Neurobiology of Aging.

[27]  Wei Chen,et al.  The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer's disease. , 2012, Toxicology letters.

[28]  J. Hong,et al.  Mutant Presenilin 2 Increases &bgr;-Secretase Activity Through Reactive Oxygen Species–Dependent Activation of Extracellular Signal–Regulated Kinase , 2012, Journal of neuropathology and experimental neurology.

[29]  The Role of Clusterin in Alzheimer’s Disease: Pathways, Pathogenesis, and Therapy , 2012, Molecular Neurobiology.

[30]  D. Holtzman,et al.  CSF biomarkers for Alzheimer's disease: current utility and potential future use , 2011, Neurobiology of Aging.

[31]  H. Geekiyanage,et al.  MicroRNA-137/181c Regulates Serine Palmitoyltransferase and In Turn Amyloid β, Novel Targets in Sporadic Alzheimer's Disease , 2011, The Journal of Neuroscience.

[32]  S. Hébert,et al.  Alzheimer-specific variants in the 3'UTR of Amyloid precursor protein affect microRNA function , 2011, Molecular Neurodegeneration.

[33]  K. Marcus,et al.  The AICD interacting protein DAB1 is up-regulated in Alzheimer frontal cortex brain samples and causes deregulation of proteins involved in gene expression changes. , 2011, Current Alzheimer research.

[34]  David M Holtzman,et al.  Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance , 2011, Science Translational Medicine.

[35]  Peng Sun,et al.  MicroRNA 802 stimulates ROMK channels by suppressing caveolin-1. , 2011, Journal of the American Society of Nephrology : JASN.

[36]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[37]  Hilkka Soininen,et al.  Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations , 2011, Neurobiology of Aging.

[38]  Jason J. Corneveaux,et al.  CR1 is associated with amyloid plaque burden and age‐related cognitive decline , 2011, Annals of neurology.

[39]  F. Lopera,et al.  Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study , 2011, The Lancet Neurology.

[40]  S. Hébert,et al.  In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs , 2011, Journal of neurochemistry.

[41]  Y. Liu,et al.  PICALM and CR1 variants are not associated with sporadic Alzheimer's disease in Chinese patients. , 2011, Journal of Alzheimer's disease : JAD.

[42]  Jürgen Götz,et al.  Target Gene Repression Mediated by miRNAs miR-181c and miR-9 Both of Which Are Down-regulated by Amyloid-β , 2011, Journal of Molecular Neuroscience.

[43]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[44]  Puneetpal Singh,et al.  A susceptible haplotype within APOE gene influences BMD and intensifies the osteoporosis risk in postmenopausal women of Northwest India. , 2010, Maturitas.

[45]  Luc Buée,et al.  Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. , 2010, Human molecular genetics.

[46]  A. Işık,et al.  Late onset Alzheimer’s disease in older people , 2010, Clinical interventions in aging.

[47]  F. Tagliavini,et al.  Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features , 2010, Acta Neuropathologica.

[48]  D. Holtzman,et al.  Biomarkers in translational research of Alzheimer’s Disease , 2010, Neuropharmacology.

[49]  J. Herz,et al.  ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling , 2010, Proceedings of the National Academy of Sciences.

[50]  T. Preiss,et al.  Neuronal MicroRNA Deregulation in Response to Alzheimer's Disease Amyloid-β , 2010, PloS one.

[51]  A. Bertram.  Medical image. Angina bullosa haemorrhagica. , 2010, The New Zealand medical journal.

[52]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[53]  P. Scheltens,et al.  MicroRNA Analysis in the Spinal Fluid of Alzheimer Patients: A Methodological Feasibility Study , 2010 .

[54]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[55]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[56]  Anchaleekorn Somkasetrin,et al.  Determination of the Apo E genotype using LightCycler Apo E mutation detection kit. , 2009, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[57]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[58]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[59]  O. Maes,et al.  MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders , 2009, Current genomics.

[60]  S. Hébert,et al.  Alterations of the microRNA network cause neurodegenerative disease , 2009, Trends in Neurosciences.

[61]  I. Plante,et al.  MicroRNA-298 and MicroRNA-328 Regulate Expression of Mouse β-Amyloid Precursor Protein-converting Enzyme 1* , 2009, Journal of Biological Chemistry.

[62]  R. Khera,et al.  Complement Receptor 1: Disease associations and therapeutic implications , 2008, Molecular Immunology.

[63]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[64]  U. Wojda,et al.  Aneuploidy, chromosomal missegregation, and cell cycle reentry in Alzheimer's disease. , 2009, Acta neurobiologiae experimentalis.

[65]  Qihong Huang,et al.  MicroRNAs can regulate human APP levels , 2008, Molecular Neurodegeneration.

[66]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[67]  S. Small,et al.  Retromer sorting: a pathogenic pathway in late-onset Alzheimer disease. , 2008, Archives of neurology.

[68]  Yasuyoshi Watanabe,et al.  A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia , 2008, Annals of neurology.

[69]  A. Roses,et al.  Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways , 2008 .

[70]  H. Schipper.  Biomarker potential of heme oxygenase-1 in Alzheimer's disease and mild cognitive impairment. , 2007, Biomarkers in medicine.

[71]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[72]  T. Wassmer,et al.  A loss-of-function screen reveals SNX5 and SNX6 as potential components of the mammalian retromer , 2006, Journal of Cell Science.

[73]  F. LaFerla,et al.  Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles* , 2006, Journal of Biological Chemistry.

[74]  Rena Li,et al.  Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes , 2006, Neurobiology of Aging.

[75]  S. Small,et al.  Sorting through the Cell Biology of Alzheimer's Disease: Intracellular Pathways to Pathogenesis , 2006, Neuron.

[76]  M. Tusié-Luna,et al.  Founder effect for the Ala431Glu mutation of the presenilin 1 gene causing early-onset Alzheimer’s disease in Mexican families , 2006, Neurogenetics.

[77]  K. Blennow,et al.  CSF Biomarkers for Alzheimer’s Disease: Levels of β-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival , 2006, Dementia and Geriatric Cognitive Disorders.

[78]  E. Mandelkow,et al.  Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy , 2006, Journal of Biological Chemistry.

[79]  L. Honig,et al.  Model‐guided microarray implicates the retromer complex in Alzheimer's disease , 2005, Annals of neurology.

[80]  B. Hyman,et al.  Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[81]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[82]  F. Baas,et al.  The unfolded protein response is activated in Alzheimer’s disease , 2005, Acta Neuropathologica.

[83]  Hyoung-Gon Lee,et al.  Tau phosphorylation in Alzheimer's disease: pathogen or protector? , 2005, Trends in molecular medicine.

[84]  M. Seaman,et al.  Recycle your receptors with retromer. , 2005, Trends in cell biology.

[85]  P. Davies,et al.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms , 2003, Journal of neurochemistry.

[86]  A. Tomasselli,et al.  Employing a superior BACE1 cleavage sequence to probe cellular APP processing , 2003, Journal of neurochemistry.

[87]  D. Selkoe.  Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. , 2002, The Journal of clinical investigation.

[88]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[89]  B. Ghetti,et al.  Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Aβ42 production , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[90]  M. Vitek,et al.  Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[91]  J. H. Lee,et al.  A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. , 2001, JAMA.

[92]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[93]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[94]  J. Pasquini,et al.  Defective ubiquitination of cerebral proteins in Alzheimer's disease , 2000, Journal of neuroscience research.

[95]  A. Heicklen-Klein,et al.  Tau Promoter Confers Neuronal Specificity and Binds Sp1 and AP‐2 , 2000, Journal of neurochemistry.

[96]  A Rostagno,et al.  Apolipoprotein J (clusterin) and Alzheimer's disease , 2000, Microscopy research and technique.

[97]  P. S. St George-Hyslop,et al.  Molecular genetics of Alzheimer's disease: the role of β-amyloid and the presenilins , 2000, Current opinion in neurology.

[98]  J. Lambris,et al.  Complement and innate immunity. , 2000, Immunopharmacology.

[99]  D. Galasko,et al.  Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. , 2000, Biochemical and biophysical research communications.

[100]  L. Wahlund,et al.  Tau Immunoreactivity Detected in Human Plasma, But No Obvious Increase in Dementia , 1999, Dementia and Geriatric Cognitive Disorders.

[101]  Hugo Vanderstichele,et al.  Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.

[102]  A Hofman,et al.  Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. , 1998, Human molecular genetics.

[103]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[104]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[105]  J. Rogers,et al.  Aggregation State‐Dependent Activation of the Classical Complement Pathway by the Amyloid β Peptide , 1997, Journal of neurochemistry.

[106]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[107]  S V Faraone,et al.  Genetics of Alzheimer's disease. , 1996, Journal of the Formosan Medical Association = Taiwan yi zhi.

[108]  C. van Broeckhoven,et al.  The presenilin genes: a new gene family involved in Alzheimer disease pathology. , 1996, Human molecular genetics.

[109]  Nick C Fox,et al.  Incomplete penetrance of familial Alzheimer's disease in a pedigree with a novel presenilin-1 gene mutation , 1996, The Lancet.

[110]  E. Matsubara,et al.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[111]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[112]  D. Mann,et al.  Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down Syndrome , 1995, Annals of neurology.

[113]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[114]  T. Wisniewski,et al.  The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. , 1993, The Biochemical journal.

[115]  J. Weber,et al.  Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. , 1992, Science.

[116]  J. Hardy,et al.  Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene , 1991, Nature.

[117]  B. Ghetti,et al.  A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. , 1991, Science.

[118]  S. Swain,et al.  Lymphokines and the immune response: the central role of interleukin-2. , 1991, Current opinion in immunology.

[119]  T. Iwaki,et al.  Hydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[120]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[121]  Steven A. Johnson,et al.  Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat , 1990, Neuron.

[122]  N. Robakis,et al.  Characterization of the 5'-end region and the first two exons of the beta-protein precursor gene. , 1989, Biochemical and biophysical research communications.

[123]  M. Lerman,et al.  Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. , 1987, Science.

[124]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .